Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With <i>Clostridioides difficile</i> Infection in MODIFY I/II Participants With Cancer.

Additional subgroup analyses revealed a nonsignificant trend for a lower cumulative rate of recurrent CDI in participants with hematologic malignancy or solid tumor.

also in 5,406 other papers

However, the 90-day cumulative mortality rate was lower in those treated with bezlotoxumab compared with placebo, although this difference did not reach statistical significance (bezlotoxumab: KM estimate, 10.6%; 95% CI, 6.1% to 15.1%; placebo: KM estimate: 15.5%; 95% CI, 10.2% to 20.8%, respectively) ( Supplementary Figure 4 ).

also in 111,027 other papers